National Pension Service Sells 15,791 Shares of Hologic, Inc. (NASDAQ:HOLX)

National Pension Service lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 440,806 shares of the medical equipment provider's stock after selling 15,791 shares during the quarter. National Pension Service owned about 0.19% of Hologic worth $35,908,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of HOLX. Innealta Capital LLC purchased a new stake in Hologic during the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic in the third quarter worth about $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. purchased a new position in Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC increased its holdings in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Trading Down 1.5 %

Shares of HOLX traded down $1.20 during trading hours on Thursday, hitting $79.29. The company had a trading volume of 1,456,026 shares, compared to its average volume of 1,594,685. Hologic, Inc. has a 52-week low of $66.93 and a 52-week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock's 50 day moving average price is $81.05 and its 200 day moving average price is $78.12. The firm has a market cap of $18.42 billion, a P/E ratio of 24.17, a P/E/G ratio of 3.03 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same period in the previous year, the firm earned $0.89 EPS. The business's quarterly revenue was up 4.5% on a year-over-year basis. On average, research analysts predict that Hologic, Inc. will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Royal Bank of Canada raised their price target on Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday. Stephens reissued an "overweight" rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Finally, UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and an average target price of $89.25.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.